Researchers conducting a preclinical study in mice successfully used targeted molecular therapy to block mostly untreatable nerve tumors that develop in people with the genetic disorder Neurofibromatosis 1 (NF1). Scientists say the data provide strong rationale for testing the therapy in clinical trials for NF1.